EMEA Sexual Transmitted Disease (STD) Diagnostics Market: By Disease Type (Chlamydia and Gonorrhea, Trichomoniasis and Mycobacterium Genitalis, Syphilis, Vulvovaginal Candidiasis, Bacterial Vaginosis, Group B Streptococcus, and Herpes Simplex Virus), By Diagnostic Test Type (Cultural Test and PCR Test), By End User (Public and Private), and Country

EMEA Sexual Transmitted Disease (STD) Diagnostics Market size was valued at US$ 616.9 million in 2023 and is expected to grow at 4.3% CAGR over the forecast years 2024 - 2030. The market is driven by several key factors which are the rising prevalence of STDs, increased awareness, technological advancements, and government initiatives. STDs are a major global health concern, with millions of new cases reported each year. The World Health Organization (WHO) estimates that over 1 million people acquire a curable STI every day. These infections, caused by bacteria, viruses, or parasites, are transmitted through sexual contact. They can also be vertically transmitted from mother to child during pregnancy, childbirth, and breastfeeding.

The World Health Organization (WHO) recognizes eight pathogens linked to the highest incidence of STDs. As timely and accurate diagnosis can reduce further transmission, the demand for STD testing instruments and kits is rising, especially in emerging countries in the Middle East and Africa. The rising prevalence of STDs, such as Chlamydia, Gonorrhea, and others is a significant driver of the market growth for STD Diagnostics tests. 

However, high cost of tests, lack of awareness about Diagnostics in low-income group population, and obtaining false-positive results with a few test kits are major restraints for the sexually transmitted disease (STD) Diagnostics market. Development of new diagnostic methods, expansion of home testing, and increased focus on men's health are opportunities in the sexually transmitted disease (STD) Diagnostics market. Point-of-care testing, multiplex testing, and direct-to-consumer marketing are the trends in the sexually transmitted disease (STD) Diagnostics market.

EMEA Sexual Transmitted Disease Diagnostics Market Key Developments:

• In May 2022, Becton, Dickinson & Company launched its new fully Automated, high throughput, infectious disease molecular diagnostic platform named BD COR MX instrument which is a new analytical instrument option for the BD COR system. The three most prevalent non-viral sexually transmitted diseases (STIs) such as Chlamydia Trachomatis (CT), Neisseria Gonorrhea (GC), and Trichomonas Vaginalis (TV).